Mounjaro®
Starting from £179.99/mo
Start journey Learn moreClinical trial data gives us a clear picture: in the STEP 1 trial, adults using semaglutide 2.4mg alongside lifestyle changes lost an average of around 15% of their body weight over 68 weeks. That figure came from a structured programme, and the structure mattered. Wegovy is a prescription-only medicine requiring clinical assessment before it can be dispensed, and the practical habits you build around it shape how closely your own results track those trial outcomes. These tips are drawn from NHS England's guidance on weight-management injections and the published clinical evidence, not from anecdote.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The 15% average weight reduction in the STEP 1 trial, published in the New England Journal of Medicine, was not achieved by the injection alone. Participants followed a reduced-calorie diet and increased their physical activity alongside treatment. The medicine suppresses appetite through GLP-1 receptor activation and slows the rate at which the stomach empties, but it cannot redesign eating habits on its own. Practically, that means the trial's results are most replicable when you treat the lifestyle component as part of the prescription, not a footnote to it.
One thing many people find useful early in treatment is keeping meals smaller than usual and chewing slowly. Because semaglutide delays gastric emptying, eating quickly and then waiting to feel full can tip into discomfort. The nausea that's common in the first weeks tends to be worst after large or fatty meals. Spreading food across the day rather than front-loading at a few sittings gives the medicine's mechanism room to work without fighting your gut at the same time.
Protein deserves particular attention. Significant weight loss, however it's achieved, tends to include some muscle loss unless protein intake is kept up and some resistance activity maintained. There's no specific target on your prescription, but NHS guidance on weight-management treatment consistently flags this point, and it's worth raising with your prescriber or a dietitian early rather than retrospectively. You can read more about the full Wegovy treatment overview on our information page.
Semaglutide is injected subcutaneously (under the skin) once weekly, in the abdomen, thigh or upper arm. Rotating the injection site each week reduces the chance of localised skin reactions such as redness or thickening, which become more likely if the same spot is used repeatedly. The pen should be stored in the fridge at 2–8°C until it's first used; after that, check the Patient Information Leaflet for the exact out-of-fridge window because that detail varies by product and must not be guessed at.
Consistency of timing matters more than most people expect. Injecting on the same day each week keeps drug levels steadier, which may help keep appetite suppression more predictable across the week. The day itself is flexible, pick one that fits your routine and stick with it. If you're wondering how Wegovy sits alongside similar treatments, a factual comparison of Wegovy with other weight-loss options is on our site.
One question the prescribers at nume hear regularly is whether the day of injection affects side effects. There's no clinical trial answer to that, but choosing a day where you have a lighter schedule in the following 24 hours is a practical hedge worth considering, especially during the early dose-escalation phase when nausea is most common.
Nausea, loose stools, constipation and indigestion are the most frequently reported side effects, and the pattern in the STEP programme was consistent: they peak around dose increases and tend to ease within one to two weeks as the body adjusts. The clinical advice, reflected in the NHS semaglutide information page, is to avoid high-fat or spicy meals during this window, stay well hydrated (particularly if vomiting or diarrhoea occur) and eat smaller portions.
Dehydration from persistent GI symptoms is the risk that warrants prompt medical attention, not just tolerance. If you cannot keep fluids down for more than a day, contact your prescriber or GP. Severe, persistent stomach pain that radiates toward the back is a signal to seek urgent help, it is associated with pancreatitis, which is a known but infrequent side effect of GLP-1 medicines. The MHRA has highlighted this in published safety communications, and it should not be waited out at home.
Constipation catches people off guard because nausea gets more coverage. Increasing fibre and fluid intake from the start, rather than reactively, tends to help. If you have further questions about managing these effects or your dose progression, our frequently asked questions page covers the most common concerns, and our aftercare team is available seven days a week. Separately, if you're thinking about cost as part of your planning, the Wegovy price comparison page explains what legitimate private treatment typically involves.
Trial evidence consistently shows that weight tends to return when GLP-1 treatment stops without accompanying behaviour change. The medicine shifts appetite and makes good habits easier to build; the habits are what hold the progress when the medicine ends or is paused. This is the basis for NHS England's insistence on wrap-around lifestyle support alongside any medically supervised weight-loss treatment.
Practically, the months of treatment are an opportunity to recalibrate portion awareness, food preferences and activity levels while appetite suppression is working in your favour. Several of the people who get the most from semaglutide treatment describe building a sustainable eating pattern during the period when appetite is at its most reliably reduced, and if you want practical guidance on making the most of that window, our page on tips for getting the best results from Wegovy is worth reading alongside your clinical advice. If you'd like to understand the eligibility criteria before starting, the age and eligibility criteria for Wegovy are covered separately.
Reassessment at six months is clinically meaningful. NICE guidance on semaglutide specifies that treatment should be reviewed if weight loss is less than 5% at the maintenance dose after six months. That review is a clinical conversation about whether to continue, adjust or reconsider, not an automatic stop. At nume, every repeat order goes through a fresh clinical review; there are no auto-renewals. If you want to explore whether treatment is right for you, the starting point is a free consultation with our prescribers, and if you have come across different brand names and alternative names used for Wegovy, our dedicated page explains what they refer to and how they relate to the same treatment.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.